Details of Disease

General Information of Disease (ID: DISBPSQZ)

Disease Name	Head and neck cancer
Synonyms	head and neck tumours; head and neck neoplasm; head and neck tumors; tumour of head and neck; head/neck neoplasm; malignant neoplasm of head and neck; head and neck malignant neoplasia; cancer of the head and neck; malignant head and neck neoplasm; malignant tumour of head and neck; craniocervical region cancer; cancer of head and neck; cancer of craniocervical region; head and neck cancer; malignant tumor of the head and neck; malignant craniocervical region neoplasm; malignant tumour of the head and neck; malignant neoplasm of craniocervical region; malignant neoplasm of the head and neck; malignant tumor of head and neck; malignant head and neck tumour; malignant head and neck tumor
Disease Class	2D42: Head and neck cancer
Definition	A primary or metastatic malignant neoplasm affecting the head and neck. Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.
Disease Hierarchy	DISAT1Z9: Advanced cancer DIS1OB2G: Head and neck neoplasm DISBPSQZ: Head and neck cancer
ICD Code	ICD-11 ICD-11: 2D42 ICD-9 ICD-9: 199 Expand ICD-9 199
Disease Identifiers	MONDO ID MONDO_0005627 MESH ID D006258 UMLS CUI C0278996 MedGen ID 78920 SNOMED CT ID 255056009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bavencio	DMU9C8F	Approved	Monoclonal antibody	[1]
Bleomycin	DMNER5S	Approved	Small molecular drug	[2]
Docetaxel	DMDI269	Approved	Small molecular drug	[3]
Gefitinib	DM15F0X	Approved	Small molecular drug	[4]
Hydroxyurea	DMOQVU9	Approved	Small molecular drug	[5]
Merimepodib	DM0HS92	Approved	Small molecular drug	[6]
Methotrexate	DM2TEOL	Approved	Small molecular drug	[7]
Nimotuzumab	DM0XXD8	Approved	Monoclonal antibody	[8]
Panitumumab	DMQPD1F	Approved	Monoclonal antibody	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

This Disease is Treated as An Indication in 50 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
A140	DMEAWJT	Phase 3	Monoclonal antibody	[10]
ASP1929	DMR71ST	Phase 3	Antibody	[11]
Axalimogene filolisbac	DMAXBCB	Phase 3	NA	[12]
Cotellic	DMF9M57	Phase 3	Small molecular drug	[1]
INCB24360	DMIJGT9	Phase 3	Small molecular drug	[1]
Iseganan	DMJE6N7	Phase 3	NA	[13]
Multikine	DMMQE8G	Phase 3	NA	[1]
Oportuzumab monatox	DME7K0P	Phase 3	NA	[12]
Porfiromycin	DMVTDQ8	Phase 3	Small molecular drug	[14]
SYM-004	DMOVEDH	Phase 3	Antibody	[15]
Zalutumumab	DM52QEZ	Phase 3	Antibody	[16]
Imprime PGG	DMIUA3M	Phase 2/3	NA	[1]
VB4-845	DMGKRAJ	Phase 2/3	Antibody	[17]
ADU- S100	DMM6B2Y	Phase 2	Small molecular drug	[18]
ADU-S100	DM8HBUI	Phase 2	NA	[19]
BMX-001	DMAEYR5	Phase 2	NA	[20]
BNT113	DM2LXB1	Phase 2	Vaccine	[21]
CLR 131	DM6135B	Phase 2	Small molecular drug	[22]
E7/HSP70 DNA vaccine	DMU8FBB	Phase 2	NA	[23]
GL-0817	DM17OZM	Phase 2	Small molecular drug	[24]
INGN-225	DMF7J6D	Phase 2	Vaccine	[25]
IPI-549	DMG5Q7F	Phase 2	NA	[1]
IRX-2	DMODLN7	Phase 2	NA	[26]
Ispinesib	DMP2BWX	Phase 2	Small molecular drug	[27]
LY2606368	DM4XMF7	Phase 2	NA	[1]
MV-NIS	DMGOLCU	Phase 2	Oncolytic virus therapy	[28]
NC-6004	DMUPVLN	Phase 2	NA	[1]
PDS0101	DM37BAA	Phase 2	Vaccine	[29]
Reovirus	DMQ73AY	Phase 2	NA	[30]
RM-1929	DMVU1R9	Phase 2	NA	[1]
Seribantumab	DMYT470	Phase 2	NA	[12]
SF1126	DML10K3	Phase 2	Small molecular drug	[1]
TAS-106	DML97KB	Phase 2	Small molecular drug	[31]
Varlilumab	DMQSC5O	Phase 2	NA	[1]
Ad/PNP	DMEVR2B	Phase 1/2	Small molecular drug	[32]
DCVax-Head/Neck	DMUZQSZ	Phase 1/2	NA	[33]
EGFR antisense DNA	DMF7EX8	Phase 1/2	Antisense drug	[34]
INO-3112	DMIW227	Phase 1/2	NA	[35]
MAGE-A10 TCR	DM6H3YS	Phase 1/2	NA	[1]
Monalizumab	DMG7XHE	Phase 1/2	Antibody	[36]
NKTR-255	DM7SMNJ	Phase 1/2	NA	[37]
OBP-301	DM9MF08	Phase 1/2	NA	[38]
ADP-A2M10	DM8BOFB	Phase 1	CAR-T cell therapy	[39]
ADXS-NEO	DMFJ1OW	Phase 1	Vaccine	[1]
COTI-2	DM6K3JQ	Phase 1	NA	[1]
Dendritic cell vaccine	DMURVPF	Phase 1	Vaccine	[40]
E-7050	DMDOCNW	Phase 1	Small molecular drug	[41]
Leukocyte interleukin	DM2B0TJ	Phase 1	NA	[42]
ONYX-015	DMBVZND	Phase 1	NA	[43]
PCA062	DM1GNEH	Phase 1	NA	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 50 Drug(s)

This Disease is Treated as An Indication in 5 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AP-5346	DMWKJCB	Discontinued in Phase 2	NA	[44]
CTL-102-GDEPT	DM09CUO	Discontinued in Phase 2	NA	[45]
HumaRAD-HN	DMNEP8T	Discontinued in Phase 1	NA	[46]
Gene therapy, IFN-alpha	DMVAM18	Terminated	NA	[47]
MGBG	DM9GOT6	Terminated	Small molecular drug	[48]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AMXT-1501	DMPSRZ0	Investigative	NA	[49]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 159 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
XRCC1	OTWRV4S2	Limited	Autosomal dominant	[50]
APOBEC3B	OTHLNI51	Limited	Biomarker	[158]
ARID3B	OTUP9MS4	Limited	Biomarker	[159]
EPS8	OTZ6ES6V	Limited	Altered Expression	[160]
ERCC1	OTNPYQHI	Limited	Altered Expression	[161]
FJX1	OT8SVTSS	Limited	Altered Expression	[162]
MAP3K13	OTS93BTX	Limited	Biomarker	[163]
MAPK6	OTDDNF3Q	Limited	Biomarker	[56]
NBN	OT73B5MD	Limited	Genetic Variation	[164]
PSMA1	OTNBVM2U	Limited	Altered Expression	[165]
RHBDF1	OTCQ7UDS	Limited	Altered Expression	[166]
SLC12A9	OTR7VRAK	Limited	Biomarker	[167]
TMC8	OTUAD95X	Limited	Genetic Variation	[168]
SHQ1	OTFBXX2H	Disputed	Genetic Variation	[169]
ARTN	OTWIWGL6	moderate	Biomarker	[59]
ASAH1	OT1DNGXL	moderate	Biomarker	[170]
CD82	OTH8MC64	moderate	Genetic Variation	[171]
CDK2AP1	OTNFOHDJ	moderate	Biomarker	[172]
DNAJB7	OT4BOECZ	moderate	Biomarker	[173]
DSG1	OT11HC3A	moderate	Biomarker	[174]
FANCM	OTNJG99Z	moderate	Biomarker	[175]
GRP	OT8JDFNI	moderate	Biomarker	[71]
ING4	OT0VVG4V	moderate	Biomarker	[176]
PIWIL1	OT7CRGZ3	moderate	Altered Expression	[177]
PKD2	OTIXBU8H	moderate	Biomarker	[178]
SEC14L2	OTJST64D	moderate	Biomarker	[179]
SH3BP4	OTVIRKW7	moderate	Biomarker	[139]
SOX11	OT4LG7LA	moderate	Biomarker	[180]
ADAM12	OTZKOTDB	Strong	Biomarker	[181]
ADAM23	OTVWT6JZ	Strong	Biomarker	[182]
ALKBH1	OTADGU5D	Strong	Altered Expression	[183]
ALOX15B	OTWQQ08W	Strong	Biomarker	[184]
ANKRD36B	OT3MW415	Strong	Biomarker	[185]
ARF6	OTVV7KJO	Strong	Biomarker	[186]
ARHGEF5	OTUVGFT9	Strong	Biomarker	[187]
ARMC9	OT0MZER2	Strong	Biomarker	[188]
ASAP1	OT4DLRYY	Strong	Biomarker	[186]
C1GALT1	OT2ZSZ6P	Strong	Biomarker	[189]
CBFA2T2	OTNOIB23	Strong	Biomarker	[190]
CD151	OTF3UZS7	Strong	Altered Expression	[191]
CD247	OT45FGUX	Strong	Altered Expression	[192]
CISD2	OTVS7S2H	Strong	Biomarker	[193]
CNFN	OTSTJPBF	Strong	Biomarker	[174]
CPVL	OTOJL31C	Strong	Genetic Variation	[194]
CSMD1	OTIVDSC4	Strong	Biomarker	[195]
CYGB	OTX153DQ	Strong	Posttranslational Modification	[196]
CYP2D7	OTYJTL3S	Strong	Genetic Variation	[153]
DEFB103B	OT8RWY64	Strong	Altered Expression	[197]
DNASE1L1	OT9ZOFN9	Strong	Biomarker	[198]
DOK1	OTGVRLW6	Strong	Posttranslational Modification	[199]
DSPP	OT1TYNDN	Strong	Biomarker	[200]
EIF4G1	OT2CF1E6	Strong	Genetic Variation	[201]
ERCC6	OT2QZKSF	Strong	Genetic Variation	[202]
ESM1	OT331Y8V	Strong	Altered Expression	[203]
ESS2	OTZ08VCZ	Strong	Biomarker	[204]
EXO1	OTI87RS5	Strong	Genetic Variation	[131]
FANCB	OTMZTXB5	Strong	Biomarker	[205]
FANCD2	OTVEB5LF	Strong	Biomarker	[206]
FGF3	OT9PK2SI	Strong	Biomarker	[207]
FOXH1	OTEXJ9SL	Strong	Genetic Variation	[208]
GOLIM4	OTB5NV8A	Strong	Biomarker	[209]
GPR4	OTIBF32I	Strong	Biomarker	[210]
GSTK1	OTDNGWAF	Strong	Biomarker	[146]
GSTM2	OTG4WT05	Strong	Genetic Variation	[211]
GSTM3	OTLA2WJT	Strong	Genetic Variation	[99]
HAVCR2	OTOL603T	Strong	Biomarker	[212]
HLTF	OTRX2OSF	Strong	Genetic Variation	[131]
HOOK2	OTPO4NQV	Strong	Altered Expression	[66]
HOPX	OTBSR6C9	Strong	Biomarker	[213]
HOXD10	OT0NOWU2	Strong	Biomarker	[214]
HOXD11	OT9XGA4G	Strong	Biomarker	[214]
IGF2BP2	OT4ZSEEE	Strong	Altered Expression	[215]
ING1	OTEZBRKW	Strong	Biomarker	[216]
ING3	OTDIJXFP	Strong	Biomarker	[176]
ING5	OTRNNSFM	Strong	Biomarker	[217]
IQSEC1	OTK1PBFD	Strong	Biomarker	[186]
ITGA3	OTBCH21D	Strong	Biomarker	[218]
KIF22	OTY6X6BL	Strong	Biomarker	[219]
KIF2A	OT2WQ6QD	Strong	Altered Expression	[66]
LRIG1	OTY5HZN5	Strong	Altered Expression	[220]
LTBP3	OTME98V7	Strong	Genetic Variation	[221]
MAL	OTBM30SW	Strong	Biomarker	[222]
MLC1	OTCNZLSP	Strong	Biomarker	[223]
MTA3	OTIA6C79	Strong	Biomarker	[224]
MTMR11	OTHL2O08	Strong	Genetic Variation	[225]
MUL1	OT2JC9YR	Strong	Altered Expression	[226]
MYBBP1A	OTIVEMIU	Strong	Biomarker	[227]
MYCBPAP	OT3W21WR	Strong	Biomarker	[186]
MYL2	OT78PC0C	Strong	Biomarker	[223]
MYL9	OT6B22JB	Strong	Biomarker	[223]
MYOF	OTRFC3IJ	Strong	Altered Expression	[228]
NANS	OTMQ2FUH	Strong	Biomarker	[229]
ND4	OT4RQVAA	Strong	Genetic Variation	[230]
NLRP2	OTJA81JU	Strong	Biomarker	[231]
NOL4	OTWI587R	Strong	Posttranslational Modification	[232]
NSD3	OT3677ZG	Strong	Posttranslational Modification	[233]
OBP2A	OTBIJ5TI	Strong	Biomarker	[219]
P2RX2	OT0LF34A	Strong	Altered Expression	[111]
P2RX6	OT1FNTXA	Strong	Altered Expression	[111]
PAIP2	OTFNVLSK	Strong	Altered Expression	[234]
PALB2	OT6DNDBG	Strong	Biomarker	[131]
PCP2	OT3LUE9M	Strong	Genetic Variation	[123]
PFN2	OT5SSSA7	Strong	Biomarker	[235]
PHEX	OTG7N3J7	Strong	Biomarker	[236]
PIK3R2	OTZSUQK5	Strong	Biomarker	[190]
PIWIL4	OTDA9MY0	Strong	Altered Expression	[177]
PPP1R12C	OT9Q86JO	Strong	Biomarker	[190]
PPP1R13B	OTC88VQO	Strong	Biomarker	[190]
PPP1R1A	OTGTAGCV	Strong	Biomarker	[237]
PPP1R3B	OTVCRXEZ	Strong	Biomarker	[238]
PPP1R3C	OTEU05TX	Strong	Biomarker	[238]
PTPRT	OTV5TXNN	Strong	Posttranslational Modification	[239]
PTTG1IP	OTX21QTE	Strong	Biomarker	[240]
RAB25	OTW0W6NP	Strong	Biomarker	[241]
RAD17	OT1I93DT	Strong	Altered Expression	[242]
RAD50	OTYMU9G1	Strong	Genetic Variation	[243]
RAD51C	OTUD6SY5	Strong	Genetic Variation	[244]
RAD52	OT0OTDHI	Strong	Genetic Variation	[131]
RARS1	OTHPZ6JN	Strong	Biomarker	[245]
RASA2	OTL06RG2	Strong	Biomarker	[246]
RASSF2	OT2JHDO4	Strong	Biomarker	[69]
RBL1	OTDEBFYC	Strong	Biomarker	[247]
RBX1	OTYA1UIO	Strong	Biomarker	[248]
RECQL5	OTVZMP1Q	Strong	Genetic Variation	[131]
REG3G	OTLIUY8Z	Strong	Altered Expression	[249]
RELB	OTU3QYEF	Strong	Altered Expression	[104]
RHOBTB1	OTGE8K45	Strong	Genetic Variation	[250]
RITA1	OTUH8IPS	Strong	Biomarker	[251]
RPS27A	OTIIGGZ2	Strong	Biomarker	[137]
RPS9	OTPV69Q0	Strong	Biomarker	[252]
RRM2B	OTE8GBUR	Strong	Genetic Variation	[253]
S100A2	OTTGHJ1H	Strong	Altered Expression	[254]
S100A7	OTJFVJRF	Strong	Biomarker	[255]
SDCCAG8	OTV2ZGV9	Strong	Biomarker	[180]
SERPINB2	OT72QLZB	Strong	Biomarker	[256]
SESN1	OTSFDZWL	Strong	Biomarker	[257]
SETDB1	OTWVUA1B	Strong	Biomarker	[258]
SHMT1	OTIINA3J	Strong	Genetic Variation	[259]
SMARCA2	OTSGJ8SV	Strong	Genetic Variation	[260]
SMUG1	OT2YIOCQ	Strong	Biomarker	[261]
SNX8	OTMG63Z6	Strong	Genetic Variation	[123]
ST13	OTNML6UP	Strong	Biomarker	[262]
STUB1	OTSUYI9A	Strong	Biomarker	[263]
TAS2R13	OTSTOX5G	Strong	Genetic Variation	[264]
TAS2R5	OT5LW1K8	Strong	Altered Expression	[265]
TAX1BP1	OTGJMGJ9	Strong	Genetic Variation	[266]
TCHP	OTVDMHSY	Strong	Biomarker	[267]
TET3	OT76U3YF	Strong	Posttranslational Modification	[268]
TNFAIP2	OTRZH80H	Strong	Genetic Variation	[269]
TNFRSF10D	OTOSRDJT	Strong	Biomarker	[270]
TRIM63	OTUSWA74	Strong	Biomarker	[271]
TRIP13	OTFM3TI9	Strong	Biomarker	[272]
TSPAN31	OT8WQ83R	Strong	Biomarker	[229]
CDH19	OTH31KJO	Definitive	Altered Expression	[273]
CSMD2	OT541Z3W	Definitive	Altered Expression	[274]
EXTL3	OT2BRUBN	Definitive	Biomarker	[275]
MAGED4B	OTO37U7W	Definitive	Biomarker	[145]
OR10A4	OTYYB8SY	Definitive	Biomarker	[276]
PLK3	OT19CT2Z	Definitive	Altered Expression	[277]
------------------------------------------------------------------------------------


⏷ Show the Full List of 159 DOT(s)

This Disease Is Related to 106 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACVRL1	TTGYPTC	Limited	Biomarker	[51]
ANO1	TTOJI4S	Limited	Biomarker	[52]
CYP1B1	TTI84H7	Limited	Genetic Variation	[53]
EIF4E	TTZGCP6	Limited	Altered Expression	[54]
ERBB2	TTR5TV4	Limited	Altered Expression	[55]
MAPK12	TTYT93M	Limited	Biomarker	[56]
OGG1	TTRU01G	Limited	Biomarker	[57]
WEE1	TTJFOAL	Limited	Biomarker	[58]
AGRP	TT4DE1O	moderate	Biomarker	[59]
BIRC3	TTAIWZN	moderate	Biomarker	[60]
CDH11	TTRGWZC	moderate	Biomarker	[61]
CEBPA	TT5LWG1	moderate	Biomarker	[62]
DEK	TT1NMGV	moderate	Biomarker	[63]
DSG3	TTEO4P8	moderate	Biomarker	[64]
FCGR2A	TTXT21W	moderate	Genetic Variation	[65]
HK2	TTK02H8	moderate	Altered Expression	[66]
IL13RA2	TTMPZ7V	moderate	Altered Expression	[67]
KRT19	TT3JF9E	moderate	Biomarker	[68]
LILRB1	TTC0QRJ	moderate	Biomarker	[69]
LY6D	TTINE9B	moderate	Biomarker	[70]
MAPK3	TT1MG9E	moderate	Biomarker	[71]
MMP8	TTGA1IV	moderate	Biomarker	[72]
MUTYH	TTNB0ZK	moderate	Genetic Variation	[73]
UGCG	TTPHEX3	moderate	Altered Expression	[74]
ABCB4	TTJUXV6	Strong	Posttranslational Modification	[75]
ADH7	TT3LE7P	Strong	Genetic Variation	[76]
ALDH2	TTFLN4T	Strong	Genetic Variation	[77]
APEH	TTYWEDQ	Strong	Genetic Variation	[78]
APEX1	TTHGL48	Strong	Biomarker	[79]
ATP7B	TTOPO51	Strong	Altered Expression	[52]
BBC3	TT7JUKC	Strong	Altered Expression	[80]
BST2	TT90BJT	Strong	Biomarker	[81]
CA9	TT2LVK8	Strong	Biomarker	[82]
CALCR	TTLWS2O	Strong	Altered Expression	[83]
CEACAM6	TTIGH2W	Strong	Altered Expression	[84]
CNP	TT71P0H	Strong	Biomarker	[85]
COASY	TT4YO0Z	Strong	Biomarker	[86]
CSNK2A1	TTER6YH	Strong	Altered Expression	[87]
DCLK1	TTOHTCY	Strong	Biomarker	[88]
ECE1	TTQ9RYT	Strong	Altered Expression	[89]
ELK3	TT5OJMV	Strong	Biomarker	[90]
EPHB1	TT8MDAC	Strong	Biomarker	[90]
FAT1	TTGUJYV	Strong	Genetic Variation	[91]
FCGR1A	TTZK4I3	Strong	Biomarker	[92]
G3BP1	TTG0R8Z	Strong	Altered Expression	[93]
GAL	TTXZAJ5	Strong	Biomarker	[94]
GALC	TT5IZRB	Strong	Altered Expression	[95]
GALR1	TTX3HNZ	Strong	Biomarker	[94]
GALR2	TTBPW3J	Strong	Posttranslational Modification	[96]
GNG7	TTCMBKF	Strong	Altered Expression	[97]
GPX1	TTYAHBP	Strong	Biomarker	[98]
HPGDS	TTCYE56	Strong	Biomarker	[99]
HPSE	TTR7GJO	Strong	Biomarker	[100]
IL4R	TTDWHC3	Strong	Altered Expression	[67]
KCNA5	TTW0CMT	Strong	Altered Expression	[66]
KCNH1	TT9XKUC	Strong	Biomarker	[101]
KLK2	TTJLNAW	Strong	Altered Expression	[66]
KRT17	TTKV0EC	Strong	Altered Expression	[102]
LTB	TTHQ6US	Strong	Biomarker	[103]
LTBR	TTFO0PM	Strong	Altered Expression	[104]
MAPK1	TT4TQBX	Strong	Altered Expression	[105]
MAPKAPK2	TTMUG9D	Strong	Biomarker	[106]
MCL1	TTL53M6	Strong	Genetic Variation	[107]
MELK	TTBZOTY	Strong	Altered Expression	[108]
MMP17	TTVSZKN	Strong	Altered Expression	[109]
NUAK1	TT65FL0	Strong	Biomarker	[110]
P2RX1	TTJW7B3	Strong	Altered Expression	[111]
P2RX3	TT2THBD	Strong	Altered Expression	[111]
PAK2	TT279WO	Strong	Biomarker	[112]
PDF	TT9SL3Q	Strong	Biomarker	[113]
PDK2	TTJGCKM	Strong	Biomarker	[114]
PIK3CB	TT9H4P3	Strong	Biomarker	[115]
PKN2	TTTHO0M	Strong	Biomarker	[116]
PRAME	TTPH7T0	Strong	Biomarker	[117]
PTGIS	TTLXKZR	Strong	Genetic Variation	[118]
PTPN13	TT405FP	Strong	Altered Expression	[119]
RAD51	TTC0G1L	Strong	Genetic Variation	[120]
RARB	TTISP28	Strong	Biomarker	[121]
REL	TT1ZCTH	Strong	Biomarker	[122]
RORA	TT1TYN7	Strong	Genetic Variation	[123]
RRM1	TTWP0NS	Strong	Biomarker	[124]
SELP	TTE5VG0	Strong	Genetic Variation	[125]
SEMA4D	TT5UT28	Strong	Biomarker	[126]
SLC10A1	TTWZRY5	Strong	Biomarker	[127]
SLC23A2	TTOP832	Strong	Biomarker	[128]
SLC6A2	TTAWNKZ	Strong	Biomarker	[90]
SLC6A8	TTYUHB5	Strong	Altered Expression	[83]
STAT6	TTWOE1T	Strong	Biomarker	[129]
TACSTD2	TTP2HE5	Strong	Altered Expression	[130]
TDP2	TTYF26D	Strong	Genetic Variation	[131]
TGFA	TTTLQFR	Strong	Altered Expression	[132]
TLR8	TT8CWFK	Strong	Biomarker	[133]
TMEM97	TT9NXW4	Strong	Biomarker	[134]
TRPC4	TTX0H5W	Strong	Biomarker	[135]
TYMS	TTP1UKZ	Strong	Biomarker	[136]
UBC	TTBP3XA	Strong	Biomarker	[137]
AREG	TT76B3W	Definitive	Altered Expression	[132]
BAP1	TT47RXJ	Definitive	Biomarker	[138]
BCL2	TTFOUV4	Definitive	Altered Expression	[139]
BCL2L1	TTRE6AX	Definitive	Biomarker	[140]
CSF3	TT5TQ2W	Definitive	Altered Expression	[141]
DPYD	TTZPS91	Definitive	Biomarker	[142]
ERBB3	TTSINU2	Definitive	Altered Expression	[55]
GALNS	TTT9YPO	Definitive	Altered Expression	[143]
GSTA2	TTNLFBE	Definitive	Altered Expression	[144]
MAGEA1	TT63M7Q	Definitive	Biomarker	[145]
------------------------------------------------------------------------------------


⏷ Show the Full List of 106 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLCO6A1	DTIFXNS	Strong	Biomarker	[146]
------------------------------------------------------------------------------------

This Disease Is Related to 15 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ADH1B	DEEN9RD	Limited	Genetic Variation	[147]
CYP2A13	DEXZA9U	Limited	Biomarker	[148]
EPHX1	DELB4KP	Limited	Genetic Variation	[149]
GCLC	DESYL1F	moderate	Altered Expression	[74]
ADH1C	DEM1HNL	Strong	Genetic Variation	[76]
AKR1A1	DED2FW3	Strong	Genetic Variation	[150]
CYP1A1	DE6OQ3W	Strong	Genetic Variation	[151]
CYP2R1	DEBIHM3	Strong	Altered Expression	[152]
NAT1	DE7OAB3	Strong	Genetic Variation	[153]
NAT2	DER7TA0	Strong	Genetic Variation	[154]
PER1	DE9HF0I	Strong	Genetic Variation	[131]
SULT1A1	DEYWLRK	Strong	Genetic Variation	[155]
TGM3	DEOEB3Q	Strong	Posttranslational Modification	[156]
UGT1A6	DESD26P	Strong	Biomarker	[157]
UGT1A7	DEZO4N3	Strong	Genetic Variation	[157]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 DME(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Bleomycin FDA Label
3	Docetaxel FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
5	Hydroxyurea FDA Label
6	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
7	Methotrexate FDA Label
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7988).
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6883).
10	Clinical pipeline report, company report or official report of Klus Pharma
11	ClinicalTrials.gov (NCT03769506) ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy. U.S. National Institutes of Health.
12	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13	ClinicalTrials.gov (NCT00022373) Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer. U.S. National Institutes of Health.
14	ClinicalTrials.gov (NCT02183246) Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients. U.S. National Institutes of Health.
15	ClinicalTrials.gov (NCT02083653) Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
16	ClinicalTrials.gov (NCT00382031) Zalutumumab in Patients With Non-curable Head and Neck Cancer. U.S. National Institutes of Health.
17	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017525)
18	ClinicalTrials.gov (NCT03937141) Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer. U.S. National Institutes of Health.
19	ClinicalTrials.gov (NCT03937141) Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer. U.S. National Institutes of Health.
20	ClinicalTrials.gov (NCT04607642) Trial of BMX-001 or Placebo in Head and Neck Cancer Patients. U.S. National Institutes of Health.
21	ClinicalTrials.gov (NCT04534205) An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT). U.S.National Institutes of Health.
22	ClinicalTrials.gov (NCT04105543) CLR 131 Combined With Radiation for Head and Neck Cancer. U.S. National Institutes of Health.
23	Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis. Curr Obstet Gynecol Rep. 2014 Mar 1;3(1):18-32.
24	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
25	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019096)
26	ClinicalTrials.gov (NCT00210470) A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer. U.S. National Institutes of Health.
27	ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health.
28	ClinicalTrials.gov (NCT02364713) MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer. U.S. National Institutes of Health.
29	ClinicalTrials.gov (NCT04260126) Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (VERSATILE002). U.S. National Institutes of Health.
30	ClinicalTrials.gov (NCT01199263) Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer. U.S. National Institutes of Health.
31	ClinicalTrials.gov (NCT00737360) Phase II Study of TAS-106 to Treat Head and Neck Cancer. U.S. National Institutes of Health.
32	ClinicalTrials.gov (NCT03754933) Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer. U.S. National Institutes of Health.
33	Clinical pipeline report, company report or official report of Northwest BioTherapeutics.
34	ClinicalTrials.gov (NCT00903461) Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma. U.S. National Institutes of Health.
35	ClinicalTrials.gov (NCT02172911) A Study of VGX-3100 and INO-9012 DNA Vaccine With Electroporation in Patients With Cervical Cancer. U.S. National Institutes of Health.
36	ClinicalTrials.gov (NCT02643550) Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. U.S. National Institutes of Health.
37	ClinicalTrials.gov (NCT04616196) Study of NKTR 255 in Combination With Cetuximab in Solid Tumors. U.S. National Institutes of Health.
38	ClinicalTrials.gov (NCT02293850) Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health.
39	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022 Mar 18;12:818679.
40	ClinicalTrials.gov (NCT00404339) Vaccine Therapy in Treating Patients With Head and Neck Cancer. U.S. National Institutes of Health.
41	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7956).
42	ClinicalTrials.gov (NCT02115919) Safety Study of Multikine in the Treatment of Perianal Warts. U.S. National Institutes of Health.
43	ClinicalTrials.gov (NCT00006106) ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer. U.S. National Institutes of Health.
44	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017581)
45	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011583)
46	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014243)
47	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
48	S-adenosylmethionine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992 Dec;56(3):359-77.
49	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1276).
50	Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
51	Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.Clin Cancer Res. 2016 Jan 1;22(1):96-106. doi: 10.1158/1078-0432.CCR-15-0743. Epub 2015 Sep 15.
52	Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.Biochem J. 2019 Dec 19;476(24):3705-3719. doi: 10.1042/BCJ20190591.
53	Association of cytochrome P450 1B1 haplotypes with head and neck cancer risk.Environ Mol Mutagen. 2017 Jul;58(6):443-450. doi: 10.1002/em.22098. Epub 2017 May 28.
54	Functional and genomic analyses reveal therapeutic potential of targeting -catenin/CBP activity in head and neck cancer.Genome Med. 2018 Jul 20;10(1):54. doi: 10.1186/s13073-018-0569-7.
55	MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.Int J Cancer. 2019 Aug 1;145(3):748-762. doi: 10.1002/ijc.32170. Epub 2019 Feb 11.
56	The atypical MAPK ERK3 potently suppresses melanoma cell growth and invasiveness.J Cell Physiol. 2019 Aug;234(8):13220-13232. doi: 10.1002/jcp.27994. Epub 2018 Dec 19.
57	Reduced expression of DNA repair genes (XRCC1, XPD, and OGG1) in squamous cell carcinoma of head and neck in North India.Tumour Biol. 2012 Feb;33(1):111-9. doi: 10.1007/s13277-011-0253-7. Epub 2011 Nov 15.
58	Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition.Mol Cancer Res. 2019 May;17(5):1115-1128. doi: 10.1158/1541-7786.MCR-18-0860. Epub 2019 Jan 24.
59	Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score-Weighted Analysis.Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):929-937. doi: 10.1016/j.ijrobp.2017.06.2456. Epub 2017 Jun 27.
60	Radio-sensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2.Cell Oncol (Dordr). 2019 Feb;42(1):29-40. doi: 10.1007/s13402-018-0403-7. Epub 2018 Sep 4.
61	CDH11 inhibits proliferation and invasion in head and neck cancer.J Oral Pathol Med. 2017 Feb;46(2):89-97. doi: 10.1111/jop.12471. Epub 2016 Jul 10.
62	Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma.Cancer Res. 2007 May 15;67(10):4657-64. doi: 10.1158/0008-5472.CAN-06-4793.
63	DEK promotes HPV-positive and -negative head and neck cancer cell proliferation.Oncogene. 2015 Feb 12;34(7):868-77. doi: 10.1038/onc.2014.15. Epub 2014 Mar 10.
64	DSG3 facilitates cancer cell growth and invasion through the DSG3-plakoglobin-TCF/LEF-Myc/cyclin D1/MMP signaling pathway.PLoS One. 2013 May 30;8(5):e64088. doi: 10.1371/journal.pone.0064088. Print 2013.
65	Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.Pharmacogenomics J. 2020 Apr;20(2):350. doi: 10.1038/s41397-019-0073-5.
66	Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer.Oncotarget. 2019 Apr 30;10(32):3066-3083. doi: 10.18632/oncotarget.24684. eCollection 2019 Apr 30.
67	Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.Curr Gene Ther. 2005 Apr;5(2):213-23. doi: 10.2174/1566523053544227.
68	Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue.Oncotarget. 2016 Nov 15;7(46):76151-76158. doi: 10.18632/oncotarget.12691.
69	Cancer-associated fibroblasts promote cancer cell growth through a miR-7-RASSF2-PAR-4 axis in the tumor microenvironment.Oncotarget. 2017 Jan 3;8(1):1290-1303. doi: 10.18632/oncotarget.13609.
70	Genetic reprogramming of tumor cells by zinc finger transcription factors.Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11716-21. doi: 10.1073/pnas.0501162102. Epub 2005 Aug 4.
71	SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.Cancer Res. 2004 Sep 1;64(17):6166-73. doi: 10.1158/0008-5472.CAN-04-0504.
72	Comparison of the miRNA profiles in HPV-positive and HPV-negative tonsillar tumors and a model system of human keratinocyte clones.BMC Cancer. 2016 Jul 4;16:382. doi: 10.1186/s12885-016-2430-y.
73	XPD, APE1, and MUTYH polymorphisms increase head and neck cancer risk: effect of gene-gene and gene-environment interactions.Tumour Biol. 2015 Sep;36(10):7569-79. doi: 10.1007/s13277-015-3472-5. Epub 2015 Apr 29.
74	Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.Mol Cancer Ther. 2015 Aug;14(8):1907-15. doi: 10.1158/1535-7163.MCT-15-0171. Epub 2015 Jun 10.
75	ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growth. Sci Rep. 2014 Nov 4;4:6899.
76	A review of genetic epidemiology of head and neck cancer related to polymorphisms in metabolic genes, cell cycle control and alcohol metabolism.Acta Otorhinolaryngol Ital. 2012 Feb;32(1):1-11.
77	Validation of Alcohol Flushing Questionnaire to Identify ALDH2 Status in a Case-Control Study of Head and Neck Cancer.Alcohol Clin Exp Res. 2019 Jun;43(6):1225-1233. doi: 10.1111/acer.14049. Epub 2019 Apr 29.
78	Polymorphism of regulatory region of APEH gene (c.-521G>C, rs4855883) as a relevant predictive factor for radiotherapy induced oral mucositis and overall survival in head neck cancer patients.Oncotarget. 2018 Jul 3;9(51):29644-29653. doi: 10.18632/oncotarget.25662. eCollection 2018 Jul 3.
79	Identification of novel heterozygous Apex 1 gene variant (Glu87Gln) in patients withhead and neck cancer of Indian origin.J Cell Biochem. 2018 Nov;119(11):8851-8861. doi: 10.1002/jcb.27138. Epub 2018 Aug 4.
80	BBC3 is down-regulated with increased tumor size independently of p53 expression in head and neck cancer.Cancer Biomark. 2012;11(5):197-208. doi: 10.3233/CBM-2012-00286.
81	CD317 Signature in Head and Neck Cancer Indicates Poor Prognosis.J Dent Res. 2018 Jul;97(7):787-794. doi: 10.1177/0022034518758604. Epub 2018 Feb 27.
82	Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.Mol Pharm. 2019 Feb 4;16(2):701-708. doi: 10.1021/acs.molpharmaceut.8b00950. Epub 2018 Dec 31.
83	Chemoradiotherapy-related carotid artery inflammation in head and neck cancer patients quantified by [(18)F]FDG PET/CT.Oral Oncol. 2019 Jun;93:101-106. doi: 10.1016/j.oraloncology.2019.04.008. Epub 2019 May 1.
84	Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis.Mol Cancer. 2012 Sep 28;11:74. doi: 10.1186/1476-4598-11-74.
85	Incidence and outcomes of radiation-induced late cranial neuropathy in 10-year survivors of head and neck cancer.Oral Oncol. 2019 Aug;95:59-64. doi: 10.1016/j.oraloncology.2019.05.014. Epub 2019 Jun 8.
86	Identification of guanine nucleotide-binding protein -7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling.Int J Oncol. 2013 Apr;42(4):1427-36. doi: 10.3892/ijo.2013.1808. Epub 2013 Feb 6.
87	Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.Hum Gene Ther Clin Dev. 2017 Jun;28(2):80-86. doi: 10.1089/humc.2017.008. Epub 2017 Mar 23.
88	Evaluation of the cancer stem cell marker DCLK1 in patients with lymph node metastases of head and neck cancer.Pathol Res Pract. 2019 Dec;215(12):152698. doi: 10.1016/j.prp.2019.152698. Epub 2019 Oct 23.
89	ECE-1 overexpression in head and neck cancer is associated with poor tumor differentiation and patient outcome.Oral Dis. 2019 Jan;25(1):44-53. doi: 10.1111/odi.12935. Epub 2018 Oct 21.
90	Correction to: Advancing interdisciplinary research in head and neck cancer through a multicenter longitudinal prospective cohort study: the NETherlands QUality of life and BIomedical Cohort (NET-QUBIC) data warehouse and biobank.BMC Cancer. 2019 Oct 22;19(1):982. doi: 10.1186/s12885-019-6223-y.
91	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation.Nat Genet. 2013 Mar;45(3):253-61. doi: 10.1038/ng.2538. Epub 2013 Jan 27.
92	Psychometric testing of the Fear of Cancer Recurrence Inventory-caregiver Chinese version in cancer family caregivers in Taiwan.Psychooncology. 2018 Jun;27(6):1580-1588. doi: 10.1002/pon.4697. Epub 2018 Mar 30.
93	The roles and mechanisms of G3BP1 in tumour promotion. J Drug Target. 2019 Mar;27(3):300-305.
94	Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.Mol Carcinog. 2017 Mar;56(3):1107-1116. doi: 10.1002/mc.22577. Epub 2016 Nov 1.
95	DNA promoter hypermethylation contributes to down-regulation of galactocerebrosidase gene in lung and head and neck cancers.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11042-50. eCollection 2015.
96	Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.Cancer. 2014 Jan 15;120(2):205-13. doi: 10.1002/cncr.28411. Epub 2013 Oct 10.
97	Loss of protein expression and recurrent DNA hypermethylation of the GNG7 gene in squamous cell carcinoma of the head and neck.J Appl Genet. 2012 May;53(2):167-74. doi: 10.1007/s13353-011-0079-4. Epub 2011 Dec 20.
98	Prognostic Significance of Glutathione Peroxidase Levels (GPx1) in Head and Neck Cancers.Front Oncol. 2017 May 9;7:84. doi: 10.3389/fonc.2017.00084. eCollection 2017.
99	GSTM3 A/B polymorphism and risk for head and neck cancer: a meta-analysis.PLoS One. 2014 Jan 8;9(1):e83851. doi: 10.1371/journal.pone.0083851. eCollection 2014.
100	Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma.J Cell Mol Med. 2014 Jan;18(1):181-6. doi: 10.1111/jcmm.12179. Epub 2013 Nov 28.
101	Frequent aberrant expression of the human ether go-go (hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms and clinical implications.J Mol Med (Berl). 2012 Oct;90(10):1173-84. doi: 10.1007/s00109-012-0893-0. Epub 2012 Mar 31.
102	Decreasing cytokeratin 17 expression in head and neck cancer predicts nodal metastasis and poor prognosis: The first evidence.Clin Otolaryngol. 2018 Aug;43(4):1010-1018. doi: 10.1111/coa.13092. Epub 2018 Apr 16.
103	Lymphotoxin- Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.Clin Cancer Res. 2017 Aug 1;23(15):4388-4401. doi: 10.1158/1078-0432.CCR-16-1955. Epub 2017 Feb 14.
104	Lymphotoxin- receptor-NIK signaling induces alternative RELB/NF-B2 activation to promote metastatic gene expression and cell migration in head and neck cancer.Mol Carcinog. 2019 Mar;58(3):411-425. doi: 10.1002/mc.22938. Epub 2018 Nov 28.
105	p38 MAPK pathway and its interaction with TRF2 in cisplatin induced chemotherapeutic response in head and neck cancer.Oncogenesis. 2018 Jul 9;7(7):53. doi: 10.1038/s41389-018-0062-6.
106	MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.Oncogene. 2019 Nov;38(48):7329-7341. doi: 10.1038/s41388-019-0945-9. Epub 2019 Aug 15.
107	Responsiveness of the EAT-10 to Clinical Change in Head and Neck Cancer Patients with Dysphagia.Int J Speech Lang Pathol. 2020 Feb;22(1):78-85. doi: 10.1080/17549507.2019.1596312. Epub 2019 Apr 28.
108	MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells.Oncol Rep. 2019 Apr;41(4):2540-2548. doi: 10.3892/or.2019.6988. Epub 2019 Jan 30.
109	Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis.Neoplasia. 2009 Dec;11(12):1371-82. doi: 10.1593/neo.91326.
110	microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer.Oncotarget. 2016 Feb 16;7(7):8223-39. doi: 10.18632/oncotarget.6972.
111	P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer.Oncotarget. 2017 Jul 25;8(30):48972-48982. doi: 10.18632/oncotarget.16903.
112	PAK2-c-Myc-PKM2 axis plays an essential role in head and neck oncogenesis via regulating Warburg effect.Cell Death Dis. 2018 Aug 1;9(8):825. doi: 10.1038/s41419-018-0887-0.
113	Stabilization of G-quadruplex DNA and inhibition of Bcl-2 expression by a pyridostatin analog.Bioorg Med Chem Lett. 2016 Apr 1;26(7):1660-3. doi: 10.1016/j.bmcl.2016.02.065. Epub 2016 Feb 23.
114	Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.Cancer Lett. 2016 Feb 1;371(1):20-9. doi: 10.1016/j.canlet.2015.11.023. Epub 2015 Nov 23.
115	A PI3K/AKT Scaffolding Protein, IQ Motif-Containing GTPase Associating Protein 1 (IQGAP1), Promotes Head and Neck Carcinogenesis.Clin Cancer Res. 2020 Jan 1;26(1):301-311. doi: 10.1158/1078-0432.CCR-19-1063. Epub 2019 Oct 9.
116	Role of protein kinase N2 (PKN2) in cigarette smoke-mediated oncogenic transformation of oral cells.J Cell Commun Signal. 2018 Dec;12(4):709-721. doi: 10.1007/s12079-017-0442-2. Epub 2018 Feb 26.
117	The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005 Sep 23;122(6):835-47. doi: 10.1016/j.cell.2005.07.003.
118	Genetic polymorphisms in the prostaglandin pathway genes and risk of head and neck cancer.Oral Dis. 2015 Mar;21(2):207-15. doi: 10.1111/odi.12244. Epub 2014 Apr 28.
119	FAP-1-mediated activation of NF-kappaB induces resistance of head and neck cancer to Fas-induced apoptosis.J Cell Biochem. 2007 Jan 1;100(1):16-28. doi: 10.1002/jcb.20922.
120	Association of RAD 51 135 G/C, 172 G/T and XRCC3 Thr241Met gene polymorphisms with increased risk of head and neck cancer.Asian Pac J Cancer Prev. 2014;15(23):10457-62. doi: 10.7314/apjcp.2014.15.23.10457.
121	RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age.Oncol Rep. 2007 Jul;18(1):105-12.
122	TNF- promotes c-REL/Np63 interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer.Cancer Res. 2011 Nov 1;71(21):6867-77. doi: 10.1158/0008-5472.CAN-11-2460. Epub 2011 Sep 20.
123	Genome-wide association study identifies genes associated with neuropathy in patients with head and neck cancer.Sci Rep. 2018 Jun 8;8(1):8789. doi: 10.1038/s41598-018-27070-4.
124	RRM1 gene expression evaluated in the liquid biopsy (blood cfRNA) as a non-invasive, predictive factor for radiotherapy-induced oral mucositis and potential prognostic biomarker in head and neck cancer patients.Cancer Biomark. 2018;22(4):657-667. doi: 10.3233/CBM-171082.
125	Relationship Between -2028 C/T SELP Gene Polymorphism, Concentration of Plasma P-Selectin and Risk of Malnutrition in Head and Neck Cancer Patients.Pathol Oncol Res. 2019 Apr;25(2):741-749. doi: 10.1007/s12253-018-00578-w. Epub 2019 Jan 8.
126	Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype.Oncotarget. 2018 Jan 19;9(13):11126-11144. doi: 10.18632/oncotarget.24277. eCollection 2018 Feb 16.
127	NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy.Acta Oncol. 2019 Oct;58(10):1410-1415. doi: 10.1080/0284186X.2019.1654129. Epub 2019 Aug 21.
128	Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer.Carcinogenesis. 2009 Jun;30(6):977-81. doi: 10.1093/carcin/bgp076. Epub 2009 Apr 3.
129	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011 Aug;121(8):3100-8. doi: 10.1172/JCI43656. Epub 2011 Jul 18.
130	Trop2 inhibition suppresses the proliferation and invasion of laryngeal carcinoma cells via the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway.Mol Med Rep. 2015 Jul;12(1):865-70. doi: 10.3892/mmr.2015.3485. Epub 2015 Mar 13.
131	Assessment of DNA repair susceptibility genes identified by whole exome sequencing in head and neck cancer.DNA Repair (Amst). 2018 Jun-Jul;66-67:50-63. doi: 10.1016/j.dnarep.2018.04.005. Epub 2018 Apr 26.
132	Sheddase activity of tumor necrosis factor-alpha converting enzyme is increased and prognostically valuable in head and neck cancer.Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2913-22. doi: 10.1158/1055-9965.EPI-08-0898. Epub 2009 Oct 20.
133	Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.Clin Cancer Res. 2018 Jan 1;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. Epub 2017 Oct 23.
134	Breast Cancer (18)F-ISO-1 Uptake as a Marker of Proliferation Status.J Nucl Med. 2020 May;61(5):665-670. doi: 10.2967/jnumed.119.232363. Epub 2019 Dec 13.
135	Data-driven Analysis of TRP Channels in Cancer: Linking Variation in Gene Expression to Clinical Significance.Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):83-90.
136	Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.Int J Mol Med. 2008 Dec;22(6):709-16.
137	Identification of stable housekeeping genes in response to ionizing radiation in cancer research.Sci Rep. 2017 Mar 6;7:43763. doi: 10.1038/srep43763.
138	BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer.Clin Cancer Res. 2018 Feb 1;24(3):600-607. doi: 10.1158/1078-0432.CCR-17-1573. Epub 2017 Nov 7.
139	TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2.J Chemother. 2015 Jun;27(3):174-80. doi: 10.1179/1973947814Y.0000000234. Epub 2015 Jan 21.
140	EGF-dependent induction of BCL-xL and p21CIP1/WAF1 is highly variable in HNSCC cells--implications for EGFR-targeted therapies.Anticancer Res. 2010 Nov;30(11):4579-85.
141	Granulocyte colony-stimulating factor (G-CSF)-mediated signaling regulates type IV collagenase activity in head and neck cancer cells.Int J Cancer. 2001 Jul 1;93(1):42-6. doi: 10.1002/ijc.1297.
142	Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.Asia Pac J Clin Oncol. 2017 Apr;13(2):e11-e20. doi: 10.1111/ajco.12446. Epub 2016 Jan 21.
143	N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies.Anticancer Res. 2019 Nov;39(11):6317-6324. doi: 10.21873/anticanres.13842.
144	Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer.Chem Biol Interact. 1998 Apr 24;111-112:187-98. doi: 10.1016/s0009-2797(97)00161-0.
145	A new strategy for the diagnosis of MAGE-expressing cancers.J Immunol Methods. 2002 Aug 1;266(1-2):79-86. doi: 10.1016/s0022-1759(02)00105-9.
146	Clinical Management of Head and Neck Cancer Cases: Role of Pharmacogenetics of CYP2 and GSTs.Oncol Res Treat. 2016;39(4):221-6. doi: 10.1159/000444608. Epub 2016 Feb 26.
147	Investigating the Association between Alcohol and Risk of Head and Neck Cancer in Taiwan.Sci Rep. 2017 Aug 29;7(1):9701. doi: 10.1038/s41598-017-08802-4.
148	Hypermethylation of carcinogen metabolism genes, CYP1A1, CYP2A13 and GSTM1 genes in head and neck cancer. Oral Dis. 2010 Oct;16(7):668-73.
149	Systematic Review and Meta-Analysis of the Relationship between EPHX1 Polymorphisms and the Risk of Head and Neck Cancer.PLoS One. 2015 Apr 29;10(4):e0123347. doi: 10.1371/journal.pone.0123347. eCollection 2015.
150	Pooled analysis of alcohol dehydrogenase genotypes and head and neck cancer: a HuGE review.Am J Epidemiol. 2004 Jan 1;159(1):1-16. doi: 10.1093/aje/kwh003.
151	Tobacco carcinogen-metabolizing genes CYP1A1, GSTM1, and GSTT1 polymorphisms and their interaction with tobacco exposure influence the risk of head and neck cancer in Northeast Indian population.Tumour Biol. 2015 Aug;36(8):5773-83. doi: 10.1007/s13277-015-3246-0. Epub 2015 Feb 28.
152	Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients.Int J Cancer. 2013 Jun 1;132(11):2520-7. doi: 10.1002/ijc.27946. Epub 2012 Dec 14.
153	Association of CYP1A1 and CYP2D6 gene polymorphisms with head and neck cancer in Tunisian patients.Mol Biol Rep. 2014;41(4):2591-600. doi: 10.1007/s11033-014-3117-6. Epub 2014 Jan 22.
154	N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case-control studies.Tumour Biol. 2014 Apr;35(4):3585-95. doi: 10.1007/s13277-013-1473-9. Epub 2013 Dec 13.
155	A case-control study investigating the role of sulfotransferase 1A1 polymorphism in head and neck cancer.J Cancer Res Clin Oncol. 2006 Jul;132(7):466-72. doi: 10.1007/s00432-006-0093-9. Epub 2006 Mar 31.
156	TGM3, a candidate tumor suppressor gene, contributes to human head and neck cancer.Mol Cancer. 2013 Dec 1;12(1):151. doi: 10.1186/1476-4598-12-151.
157	Combined effect of genetic polymorphisms in phase I and II biotransformation enzymes on head and neck cancer risk.Head Neck. 2013 Jun;35(6):858-67. doi: 10.1002/hed.23054. Epub 2012 Jun 19.
158	Evidence for APOBEC3B mutagenesis in multiple human cancers.Nat Genet. 2013 Sep;45(9):977-83. doi: 10.1038/ng.2701. Epub 2013 Jul 14.
159	let-7 Modulates Chromatin Configuration and Target Gene Repression through Regulation of the ARID3B Complex.Cell Rep. 2016 Jan 26;14(3):520-533. doi: 10.1016/j.celrep.2015.12.064. Epub 2016 Jan 14.
160	Eps8 expression is significantly lower in p16(+) head and neck squamous cell carcinomas (HNSCCs) compared with p16(-) HNSCCs.Hum Pathol. 2018 Feb;72:45-51. doi: 10.1016/j.humpath.2017.10.021. Epub 2017 Oct 28.
161	Could excision repair cross-complementing group-1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?.Asia Pac J Clin Oncol. 2020 Apr;16(2):e19-e26. doi: 10.1111/ajco.13239. Epub 2019 Oct 15.
162	An Oncogenic Role for Four-Jointed Box 1 (FJX1) in Nasopharyngeal Carcinoma.Dis Markers. 2019 May 19;2019:3857853. doi: 10.1155/2019/3857853. eCollection 2019.
163	Survival of Head and Neck Cancer Cells Relies upon LZK Kinase-Mediated Stabilization of Mutant p53.Cancer Res. 2017 Sep 15;77(18):4961-4972. doi: 10.1158/0008-5472.CAN-17-0267. Epub 2017 Jul 31.
164	Association of polymorphisms and haplotypes of the NBN gene with laryngeal cancer and multiple primary tumors of the head and neck.Head Neck. 2012 Mar;34(3):376-83. doi: 10.1002/hed.21741. Epub 2011 Apr 5.
165	The transcription levels and prognostic values of seven proteasome alpha subunits in human cancers.Oncotarget. 2017 Jan 17;8(3):4501-4519. doi: 10.18632/oncotarget.13885.
166	Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth.Mol Cancer Ther. 2008 Jun;7(6):1355-64. doi: 10.1158/1535-7163.MCT-08-0104. Epub 2008 Jun 4.
167	Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells.Cell Death Dis. 2015 Mar 12;6(3):e1678. doi: 10.1038/cddis.2015.44.
168	A coding variant in TMC8 (EVER2) is associated with high risk HPV infection and head and neck cancer risk.PLoS One. 2015 Apr 8;10(4):e0123716. doi: 10.1371/journal.pone.0123716. eCollection 2015.
169	Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis.Nat Commun. 2017 Oct 20;8(1):1081. doi: 10.1038/s41467-017-01198-9.
170	Targeting acid ceramidase sensitises head and neck cancer to cisplatin.Eur J Cancer. 2016 Jan;52:163-72. doi: 10.1016/j.ejca.2015.10.056. Epub 2015 Dec 11.
171	Lack of germ line changes in KISS1 and KAI1 genes in sporadic head and neck cancer patients of Pakistani origin.Asian Pac J Cancer Prev. 2011;12(10):2767-71.
172	Expression of cyclin-dependent kinase 2-associated protein 1 confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study.J Clin Pathol. 2012 Sep;65(9):795-801. doi: 10.1136/jclinpath-2012-200893. Epub 2012 Jul 12.
173	Pseudolaric Acid B Induces Growth Inhibition and Caspase-Dependent Apoptosis on Head and Neck Cancer Cell lines through Death Receptor 5.Molecules. 2019 Oct 16;24(20):3715. doi: 10.3390/molecules24203715.
174	Analysis of gene coexpression network reveals prognostic significance of CNFN in patients with head and neck cancer.Oncol Rep. 2019 Apr;41(4):2168-2180. doi: 10.3892/or.2019.7019. Epub 2019 Feb 18.
175	The germline variants in DNA repair genes in pediatric medulloblastoma: a challenge for current therapeutic strategies.BMC Cancer. 2017 Apr 4;17(1):239. doi: 10.1186/s12885-017-3211-y.
176	Tumor-specific mutation and downregulation of ING5 detected in oral squamous cell carcinoma.Int J Cancer. 2010 Nov 1;127(9):2088-94. doi: 10.1002/ijc.25224.
177	HPV status is associated with altered PIWI-interacting RNA expression pattern in head and neck cancer.Oral Oncol. 2016 Apr;55:43-48. doi: 10.1016/j.oraloncology.2016.01.012. Epub 2016 Feb 4.
178	Exosome-delivered TRPP2 siRNA inhibits the epithelial-mesenchymal transition of FaDu cells.Oncol Lett. 2019 Feb;17(2):1953-1961. doi: 10.3892/ol.2018.9752. Epub 2018 Nov 23.
179	Prognostic significance of P53 histochemistry and DNA histogram parameters in head and neck malignancies.Anticancer Res. 2000 Sep-Oct;20(5C):4031-7.
180	Sox11 promotes head and neck cancer progression via the regulation of SDCCAG8.J Exp Clin Cancer Res. 2019 Mar 29;38(1):138. doi: 10.1186/s13046-019-1146-7.
181	A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.Oncogene. 2012 Jun 7;31(23):2888-98. doi: 10.1038/onc.2011.460. Epub 2011 Oct 10.
182	Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer.Cancer Genet Cytogenet. 2007 Feb;173(1):31-7. doi: 10.1016/j.cancergencyto.2006.09.008.
183	ALKBH overexpression in head and neck cancer: potential target for novel anticancer therapy.Sci Rep. 2019 Sep 13;9(1):13249. doi: 10.1038/s41598-019-49550-x.
184	Synergistic effect of 15-lipoxygenase 2 and radiation in killing head-and-neck cancer.Cancer Gene Ther. 2008 May;15(5):323-30. doi: 10.1038/cgt.2008.9. Epub 2008 Feb 22.
185	Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer.J Craniomaxillofac Surg. 2018 Mar;46(3):492-497. doi: 10.1016/j.jcms.2017.12.014. Epub 2017 Dec 24.
186	Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.Head Neck. 2017 Mar;39(3):476-485. doi: 10.1002/hed.24626. Epub 2016 Nov 23.
187	Increased PD-1(+) and TIM-3(+) TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.Cancer Immunol Res. 2017 May;5(5):408-416. doi: 10.1158/2326-6066.CIR-16-0333. Epub 2017 Apr 13.
188	Prophylactic NS-21 maintains the skin moisture but does not reduce the severity of radiation dermatitis in patients with head and neck cancer: a randomized control trial.Radiat Oncol. 2019 May 30;14(1):90. doi: 10.1186/s13014-019-1302-4.
189	C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer.Oncogene. 2018 Oct;37(43):5780-5793. doi: 10.1038/s41388-018-0375-0. Epub 2018 Jun 21.
190	Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer.Oral Oncol. 2018 Mar;78:56-63. doi: 10.1016/j.oraloncology.2018.01.014. Epub 2018 Feb 20.
191	CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.Clin Oral Investig. 2017 Jun;21(5):1503-1508. doi: 10.1007/s00784-016-1911-3. Epub 2016 Jul 21.
192	Change in CD3-chain expression is an independent predictor of disease status in head and neck cancer patients.Int J Cancer. 2016 Jul 1;139(1):122-9. doi: 10.1002/ijc.30046. Epub 2016 Mar 8.
193	CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer.Cancer Lett. 2018 Sep 28;432:180-190. doi: 10.1016/j.canlet.2018.06.018. Epub 2018 Jun 18.
194	Human papillomavirus seropositivity and risks of head and neck cancer.Int J Cancer. 2007 Feb 15;120(4):825-32. doi: 10.1002/ijc.22330.
195	Clinical Significance of CUB and Sushi Multiple Domains 1 Inactivation in Head and Neck Squamous Cell Carcinoma.Int J Mol Sci. 2018 Dec 12;19(12):3996. doi: 10.3390/ijms19123996.
196	Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer.Br J Cancer. 2009 Jul 7;101(1):139-44. doi: 10.1038/sj.bjc.6605121.
197	Human papillomavirus oncogenic E6 protein regulates human -defensin 3 (hBD3) expression via the tumor suppressor protein p53.Oncotarget. 2016 May 10;7(19):27430-44. doi: 10.18632/oncotarget.8443.
198	Systematic analysis of survival-associated alternative splicing signatures uncovers prognostic predictors for head and neck cancer.J Cell Physiol. 2019 Sep;234(9):15836-15846. doi: 10.1002/jcp.28241. Epub 2019 Feb 10.
199	Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers.Int J Cancer. 2012 Jun 1;130(11):2484-94. doi: 10.1002/ijc.26299. Epub 2011 Sep 22.
200	A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.Mol Cancer Ther. 2016 Nov;15(11):2620-2629. doi: 10.1158/1535-7163.MCT-16-0332. Epub 2016 Aug 22.
201	Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1): a target for cancer therapeutic intervention?.Cancer Cell Int. 2019 Aug 31;19:224. doi: 10.1186/s12935-019-0947-2. eCollection 2019.
202	Single-nucleotide polymorphisms in nucleotide excision repair genes, cigarette smoking, and the risk of head and neck cancer.Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1428-45. doi: 10.1158/1055-9965.EPI-13-0185. Epub 2013 May 29.
203	Functional analysis of ESM1 by siRNA knockdown in primary and metastatic head and neck cancer cells.J Oral Pathol Med. 2018 Jan;47(1):40-47. doi: 10.1111/jop.12648. Epub 2017 Oct 30.
204	Volatilomic insight of head and neck cancer via the effects observed on saliva metabolites.Sci Rep. 2018 Dec 7;8(1):17725. doi: 10.1038/s41598-018-35854-x.
205	X-linked VACTERL with hydrocephalus syndrome: further delineation of the phenotype caused by FANCB mutations. Am J Med Genet A. 2011 Oct;155A(10):2370-80. doi: 10.1002/ajmg.a.33913. Epub 2011 Sep 9.
206	Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.Mol Med Rep. 2015 Jun;11(6):4605-10. doi: 10.3892/mmr.2015.3288. Epub 2015 Jan 30.
207	Hypomethylated Fgf3 is a potential biomarker for early detection of oral cancer in mice treated with the tobacco carcinogen dibenzo[def,p]chrysene.PLoS One. 2017 Oct 26;12(10):e0186873. doi: 10.1371/journal.pone.0186873. eCollection 2017.
208	The interplay between alcohol consumption, oral hygiene, ALDH2 and ADH1B in the risk of head and neck cancer.Int J Cancer. 2014 Nov 15;135(10):2424-36. doi: 10.1002/ijc.28885. Epub 2014 Apr 19.
209	Golgi integral membrane protein 4 manipulates cellular proliferation, apoptosis, and cell cycle in human head and neck cancer.Biosci Rep. 2018 Aug 31;38(4):BSR20180454. doi: 10.1042/BSR20180454. Print 2018 Aug 31.
210	The Proton-Sensing G-Protein Coupled Receptor GPR4 Promotes Angiogenesis in Head and Neck Cancer.PLoS One. 2016 Apr 14;11(4):e0152789. doi: 10.1371/journal.pone.0152789. eCollection 2016.
211	Meta-analysis of glutathione S-transferase M1 genotype and risk toward head and neck cancer.Head Neck. 2006 Mar;28(3):217-24. doi: 10.1002/hed.20295.
212	TIM-3 expression and its association with overall survival in primary osteosarcoma.Oncol Lett. 2019 Nov;18(5):5294-5300. doi: 10.3892/ol.2019.10855. Epub 2019 Sep 12.
213	HOPX functions as a tumour suppressor in head and neck cancer.Sci Rep. 2016 Dec 9;6:38758. doi: 10.1038/srep38758.
214	POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer.Oncotarget. 2014 Sep 30;5(18):8803-15. doi: 10.18632/oncotarget.2492.
215	Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway.Oncotarget. 2012 Dec;3(12):1641-52. doi: 10.18632/oncotarget.785.
216	Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas.Gene. 2005 Aug 15;356:109-17. doi: 10.1016/j.gene.2005.02.014.
217	Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5.Genome Biol. 2019 Jan 14;20(1):12. doi: 10.1186/s13059-018-1604-0.
218	Regulation of ITGA3 by the anti-tumor miR-199 family inhibits cancer cell migration and invasion in head and neck cancer.Cancer Sci. 2017 Aug;108(8):1681-1692. doi: 10.1111/cas.13298. Epub 2017 Jul 4.
219	Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer.Oncol Rep. 2009 Nov;22(5):1039-43. doi: 10.3892/or_00000533.
220	LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling.Oncogene. 2014 Mar 13;33(11):1375-84. doi: 10.1038/onc.2013.98. Epub 2013 Apr 29.
221	Reliability and psychometric validity of Hindi version of Depression, Anxiety and Stress Scale-21 (DASS-21) for Hindi speaking Head Neck Cancer and Oral Potentially Malignant Disorders Patients.J Cancer Res Ther. 2019 Jul-Sep;15(3):653-658. doi: 10.4103/jcrt.JCRT_281_17.
222	T-lymphocyte maturation-associated protein gene as a candidate metastasis suppressor for head and neck squamous cell carcinomas.Cancer Sci. 2009 May;100(5):873-80. doi: 10.1111/j.1349-7006.2009.01132.x.
223	Automatic replanning of VMAT plans for different treatment machines: Atemplate-based approach using constrained optimization.Strahlenther Onkol. 2018 Oct;194(10):921-928. doi: 10.1007/s00066-018-1319-x. Epub 2018 May 30.
224	MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma.Front Oncol. 2019 Aug 27;9:816. doi: 10.3389/fonc.2019.00816. eCollection 2019.
225	Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.Mol Cancer Ther. 2015 Feb;14(2):608-19. doi: 10.1158/1535-7163.MCT-14-0735-T. Epub 2014 Dec 10.
226	HSPA5 negatively regulates lysosomal activity through ubiquitination of MUL1 in head and neck cancer.Autophagy. 2018;14(3):385-403. doi: 10.1080/15548627.2017.1414126. Epub 2018 Feb 21.
227	Regulation and function of Myb-binding protein 1A (MYBBP1A) in cellular senescence and pathogenesis of head and neck cancer.Cancer Lett. 2015 Mar 28;358(2):191-199. doi: 10.1016/j.canlet.2014.12.042. Epub 2014 Dec 24.
228	High expression of myoferlin is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with HPV-status.Oncotarget. 2016 Apr 5;7(14):18665-77. doi: 10.18632/oncotarget.7625.
229	Quantitative proteomics unveiled: Regulation of DNA double strand break repair by EGFR involves PARP1.Radiother Oncol. 2015 Sep;116(3):423-30. doi: 10.1016/j.radonc.2015.09.018. Epub 2015 Sep 25.
230	Mutations and polymorphisms in mitochondrial DNA in head and neck cancer cell lines.Acta Otorhinolaryngol Ital. 2006 Aug;26(4):185-90.
231	Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer.Br J Cancer. 2010 Dec 7;103(12):1822-30. doi: 10.1038/sj.bjc.6605980. Epub 2010 Nov 9.
232	Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer.Oncol Rep. 2014 Feb;31(2):1014-20. doi: 10.3892/or.2013.2927. Epub 2013 Dec 16.
233	WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.Sci Rep. 2017 Jan 19;7:40664. doi: 10.1038/srep40664.
234	Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance.Br J Cancer. 2006 May 22;94(10):1516-23. doi: 10.1038/sj.bjc.6603108.
235	Profilin 2 Promotes Proliferation and Metastasis of Head and Neck Cancer Cells by Regulating PI3K/AKT/-Catenin Signaling Pathway.Oncol Res. 2019 Sep 23;27(9):1079-1088. doi: 10.3727/096504019X15579146061957. Epub 2019 May 15.
236	Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.Br J Radiol. 2011 Oct;84(1006):903-18. doi: 10.1259/bjr/25012212.
237	Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.Cancer Gene Ther. 2013 Oct;20(10):582-9. doi: 10.1038/cgt.2013.55. Epub 2013 Sep 13.
238	Posttraumatic growth in head and neck cancer survivors: Is it possible and what are the correlates?.Psychooncology. 2018 Jun;27(6):1517-1523. doi: 10.1002/pon.4682. Epub 2018 Apr 16.
239	Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.Oncogene. 2016 Mar 3;35(9):1163-9. doi: 10.1038/onc.2015.171. Epub 2015 May 18.
240	PTTG and PBF Functionally Interact with p53 and Predict Overall Survival in Head and Neck Cancer.Cancer Res. 2018 Oct 15;78(20):5863-5876. doi: 10.1158/0008-5472.CAN-18-0855. Epub 2018 Aug 28.
241	Rab25 regulates invasion and metastasis in head and neck cancer.Clin Cancer Res. 2013 Mar 15;19(6):1375-88. doi: 10.1158/1078-0432.CCR-12-2858. Epub 2013 Jan 22.
242	Downregulation of RAD17 in head and neck cancer.Head Neck. 2008 Jan;30(1):35-42. doi: 10.1002/hed.20660.
243	The MRN protein complex genes: MRE11 and RAD50 and susceptibility to head and neck cancers.Mol Cancer. 2013 Sep 30;12(1):113. doi: 10.1186/1476-4598-12-113.
244	Rad51C: a novel suppressor gene modulates the risk of head and neck cancer.Mutat Res. 2014 Apr;762:47-54. doi: 10.1016/j.mrfmmm.2014.02.007. Epub 2014 Mar 12.
245	The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res. 2018 Feb 1;24(3):659-673.
246	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.BMC Cancer. 2016 Feb 29;16:170. doi: 10.1186/s12885-016-2209-1.
247	Pocket proteins suppress head and neck cancer.Cancer Res. 2012 Mar 1;72(5):1280-9. doi: 10.1158/0008-5472.CAN-11-2833. Epub 2012 Jan 11.
248	Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer.Head Neck. 2015 May;37(5):727-34. doi: 10.1002/hed.23663. Epub 2014 Jun 18.
249	Expression of REG III and prognosis in head and neck cancer.Oncol Rep. 2013 Aug;30(2):573-8. doi: 10.3892/or.2013.2521. Epub 2013 Jun 5.
250	Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer.J Cancer Res Clin Oncol. 2006 Jan;132(1):19-27. doi: 10.1007/s00432-005-0033-0. Epub 2005 Sep 17.
251	RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.Redox Biol. 2017 Oct;13:219-227. doi: 10.1016/j.redox.2017.05.025. Epub 2017 Jun 1.
252	Events of alternative splicing in head and neck cancer via RNA sequencing - an update.BMC Genomics. 2019 Jun 3;20(1):442. doi: 10.1186/s12864-019-5794-y.
253	Investigation of the association of hRRM1 and p53R2 gene polymorphisms in head and neck squamous cell carcinomas.Med Oncol. 2014 Jul;31(7):12. doi: 10.1007/s12032-014-0012-x. Epub 2014 May 27.
254	Down-regulation of S100A2 in lymph node metastases of head and neck cancer.Head Neck. 2007 Mar;29(3):236-43. doi: 10.1002/hed.20511.
255	Nuclear S100A7 is associated with poor prognosis in head and neck cancer.PLoS One. 2010 Aug 3;5(8):e11939. doi: 10.1371/journal.pone.0011939.
256	Plasminogen activator inhibitor-1 as regulator of tumor-initiating cell properties in head and neck cancers.Head Neck. 2016 Apr;38 Suppl 1:E895-904. doi: 10.1002/hed.24124. Epub 2015 Jul 16.
257	Suppression of SESN1 reduces cisplatin and hyperthermia resistance through increasing reactive oxygen species (ROS) in human maxillary cancer cells.Int J Hyperthermia. 2018 Dec;35(1):269-278. doi: 10.1080/02656736.2018.1496282. Epub 2018 Oct 9.
258	Knockdown of SET Domain, Bifurcated 1 suppresses head and neck cancer cell viability and wound-healing ability in vitro.Turk J Biol. 2019 Oct 14;43(5):281-292. doi: 10.3906/biy-1903-71. eCollection 2019.
259	DNMT3B C46359T and SHMT1 C1420T polymorphisms in the folate pathway in carcinogenesis of head and neck.Mol Biol Rep. 2014 Feb;41(2):581-9. doi: 10.1007/s11033-013-2895-6. Epub 2013 Dec 22.
260	Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.Cancer Med. 2014 Apr;3(2):426-33. doi: 10.1002/cam4.201. Epub 2014 Feb 12.
261	Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.PLoS One. 2019 Feb 28;14(2):e0213111. doi: 10.1371/journal.pone.0213111. eCollection 2019.
262	Carboxy-terminus Hsc70 interacting protein exerts a tumor inhibition function in head and neck cancer.Oncol Rep. 2017 Sep;38(3):1629-1636. doi: 10.3892/or.2017.5827. Epub 2017 Jul 17.
263	Cancer stem-like cell related protein CD166 degrades through E3 ubiquitin ligase CHIP in head and neck cancer.Exp Cell Res. 2017 Apr 1;353(1):46-53. doi: 10.1016/j.yexcr.2017.03.005. Epub 2017 Mar 6.
264	Variation in the gene TAS2R13 is associated with differences in alcohol consumption in patients with head and neck cancer.Chem Senses. 2012 Oct;37(8):737-44. doi: 10.1093/chemse/bjs063. Epub 2012 Jul 23.
265	Effects of chemotherapy on gene expression of lingual taste receptors in patients with head and neck cancer.Laryngoscope. 2016 Mar;126(3):E103-9. doi: 10.1002/lary.25679. Epub 2015 Sep 30.
266	Analysis of the TAX1BP1 gene in head and neck cancer patients.Braz J Otorhinolaryngol. 2010 Mar-Apr;76(2):193-8. doi: 10.1590/S1808-86942010000200008.
267	4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer.Cancer Res. 2019 Apr 1;79(7):1438-1450. doi: 10.1158/0008-5472.CAN-18-1220. Epub 2019 Mar 20.
268	Association of TET3 epigenetic inactivation with head and neck cancer.Oncotarget. 2018 May 11;9(36):24480-24493. doi: 10.18632/oncotarget.25333. eCollection 2018 May 11.
269	A functional TNFAIP2 3'-UTR rs8126 genetic polymorphism contributes to risk of esophageal squamous cell carcinoma.PLoS One. 2014 Nov 10;9(11):e109318. doi: 10.1371/journal.pone.0109318. eCollection 2014.
270	Interaction between N-cadherin and decoy receptor-2 regulates apoptosis in head and neck cancer.Oncotarget. 2018 Jul 31;9(59):31516-31530. doi: 10.18632/oncotarget.25846. eCollection 2018 Jul 31.
271	Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer.Brain Behav Immun. 2018 Nov;74:291-295. doi: 10.1016/j.bbi.2018.09.013. Epub 2018 Sep 11.
272	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.Nat Commun. 2014 Jul 31;5:4527. doi: 10.1038/ncomms5527.
273	Delineation and candidate gene mutation screening of the 18q22 minimal region of deletion in head and neck squamous cell carcinoma.Oncogene. 2002 Jul 25;21(32):5016-23. doi: 10.1038/sj.onc.1205626.
274	Identification of two new members of the CSMD gene family.Genomics. 2003 Sep;82(3):412-5. doi: 10.1016/s0888-7543(03)00149-6.
275	Ad5CMVp53 gene therapy for locally advanced prostate cancer--where do we stand?.World J Urol. 2000 Apr;18(2):121-4. doi: 10.1007/s003450050183.
276	Functional and T cell receptor gene usage analysis of cytotoxic T lymphocytes in fresh tumor-infiltrating lymphocytes from human head and neck cancer.Jpn J Cancer Res. 1995 May;86(5):477-83. doi: 10.1111/j.1349-7006.1995.tb03081.x.
277	PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer.Genes Chromosomes Cancer. 2000 Mar;27(3):332-6. doi: 10.1002/(sici)1098-2264(200003)27:3<332::aid-gcc15>3.0.co;2-k.